Andy Chen
Stock Analyst at Wolfe Research
(3.60)
# 799
Out of 5,163 analysts
41
Total ratings
60%
Success rate
25.56%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andy Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VERA Vera Therapeutics | Upgrades: Outperform | $88 | $39.96 | +120.22% | 3 | Mar 11, 2026 | |
| APGE Apogee Therapeutics | Initiates: Peer Perform | n/a | $71.90 | - | 1 | Jan 7, 2026 | |
| IMVT Immunovant | Upgrades: Outperform | $50 | $24.41 | +104.83% | 3 | Jan 6, 2026 | |
| KYMR Kymera Therapeutics | Downgrades: Peer Perform | n/a | $79.03 | - | 3 | Jan 6, 2026 | |
| VRTX Vertex Pharmaceuticals | Upgrades: Outperform | $548 | $469.34 | +16.76% | 2 | Jan 6, 2026 | |
| ARGX argenx SE | Downgrades: Peer Perform | n/a | $700.45 | - | 3 | Nov 24, 2025 | |
| NTLA Intellia Therapeutics | Downgrades: Peer Perform | n/a | $12.76 | - | 3 | Nov 12, 2025 | |
| APLS Apellis Pharmaceuticals | Initiates: Peer Perform | n/a | $18.94 | - | 1 | Nov 6, 2025 | |
| ALNY Alnylam Pharmaceuticals | Upgrades: Peer Perform | n/a | $313.41 | - | 3 | Aug 4, 2025 | |
| BBIO BridgeBio Pharma | Initiates: Outperform | $49 | $69.41 | -29.40% | 1 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $16.40 | - | 1 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $61 | $17.13 | +256.10% | 3 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $64.81 | - | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $37.49 | - | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $20 | $40.00 | -50.00% | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $24.00 | -20.83% | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $92.54 | - | 1 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $29.51 | - | 3 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $444.83 | - | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $28.68 | - | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $71.19 | - | 1 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $48.75 | - | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $28.06 | -39.42% | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $42 | $139.50 | -69.89% | 1 | Feb 15, 2024 |
Vera Therapeutics
Mar 11, 2026
Upgrades: Outperform
Price Target: $88
Current: $39.96
Upside: +120.22%
Apogee Therapeutics
Jan 7, 2026
Initiates: Peer Perform
Price Target: n/a
Current: $71.90
Upside: -
Immunovant
Jan 6, 2026
Upgrades: Outperform
Price Target: $50
Current: $24.41
Upside: +104.83%
Kymera Therapeutics
Jan 6, 2026
Downgrades: Peer Perform
Price Target: n/a
Current: $79.03
Upside: -
Vertex Pharmaceuticals
Jan 6, 2026
Upgrades: Outperform
Price Target: $548
Current: $469.34
Upside: +16.76%
argenx SE
Nov 24, 2025
Downgrades: Peer Perform
Price Target: n/a
Current: $700.45
Upside: -
Intellia Therapeutics
Nov 12, 2025
Downgrades: Peer Perform
Price Target: n/a
Current: $12.76
Upside: -
Apellis Pharmaceuticals
Nov 6, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $18.94
Upside: -
Alnylam Pharmaceuticals
Aug 4, 2025
Upgrades: Peer Perform
Price Target: n/a
Current: $313.41
Upside: -
BridgeBio Pharma
Jun 17, 2025
Initiates: Outperform
Price Target: $49
Current: $69.41
Upside: -29.40%
Jun 17, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $16.40
Upside: -
May 19, 2025
Upgrades: Outperform
Price Target: $61
Current: $17.13
Upside: +256.10%
Feb 4, 2025
Initiates: Outperform
Price Target: n/a
Current: $64.81
Upside: -
Feb 4, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $37.49
Upside: -
Feb 4, 2025
Initiates: Outperform
Price Target: $20
Current: $40.00
Upside: -50.00%
Feb 4, 2025
Initiates: Outperform
Price Target: $19
Current: $24.00
Upside: -20.83%
Oct 1, 2024
Initiates: Outperform
Price Target: n/a
Current: $92.54
Upside: -
Sep 27, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $29.51
Upside: -
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $444.83
Upside: -
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $28.68
Upside: -
Apr 10, 2024
Upgrades: Outperform
Price Target: n/a
Current: $71.19
Upside: -
Feb 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $48.75
Upside: -
Feb 15, 2024
Initiates: Outperform
Price Target: $17
Current: $28.06
Upside: -39.42%
Feb 15, 2024
Initiates: Outperform
Price Target: $42
Current: $139.50
Upside: -69.89%